[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607899":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":27,"overallOfficials":13,"centralContacts":37,"locations":47,"responsibleParty":66,"collaborators":69,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":13,"enrollmentInfo":82,"targetDuration":13,"studyType":85,"phases":86,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":50,"whyStopped":13,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"University of British Columbia","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Feasibility and Acceptability of Self-collected Vaginal DNA to Assess for the Presence of Mutations Related to EC or EC Precursors","Feasibility will be measured by enrollment and adherence rates. Enrollment is defined as interested individuals completing the first round of self-collection. Adherence is defined as compliance with returning vaginal DNA samples, completing the health questionnaire, and submitting the exit survey. Acceptability will be measured through responses to a questionnaire post-self-collection and an exit survey, evaluating ease and overall experience with the self-collection process.","Through study completion, anticipated 1-2 years",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","SCREENING",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21],{"label":22,"type":23,"description":24,"interventionNames":25},"Vaginal self-collection","EXPERIMENTAL","Participants will receive up to three at-home collection kits with a vaginal swab for DNA collection, a vaginal swab for microbiome sampling, a vaginal pH testing kit, and instructions on how to perform the sample collection. Vaginal DNA will be collected using Zymo DNA\u002FRNA Shield, vaginal microbiome DNA will be collected using Genotek OMNIgene, and vaginal pH will be collected using GYNEX pHem-Alert.\n\nParticipants with abnormal findings will be referred to a gynecologist or gynecologic oncologist for appropriate clinical assessment. Those with negative pathology will remain in the study. The self-collection will be repeated up to two more times, at eight-to-nine-month intervals, up to three successful self-collections.",[26],"Combination Product: Vaginal DNA swab, microbiome swab and pH test",[28],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"COMBINATION_PRODUCT","Vaginal DNA swab, microbiome swab and pH test","Participants will receive up to three at-home collection kits with a vaginal swab for DNA collection, a vaginal swab for microbiome sampling, a vaginal pH testing kit, and instructions on how to perform the sample collection. Vaginal DNA will be collected using Zymo DNA\u002FRNA Shield, vaginal microbiome DNA will be collected using Genotek OMNIgene, and vaginal pH will be collected using GYNEX pHem-Alert. Those with abnormal findings will be referred to a gynecologist or gynecologic oncologist for appropriate clinical assessment. Those with negative pathology will remain in the study. The self-collection will be repeated up to two more times, at eight-to-nine-month intervals, up to three successful self-collections.",[22],[34,35,36],"Zymo DNA\u002FRNA Shield Swab Kit","DNAGenotek Inc. OMNIgene (OMR-130) Vaginal Microbiome Swab Kit","Gynex pHem-Alert Vaginal pH test",[38,44],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},"Aline Talhouk, PhD","CONTACT","604-875-4111","21365","a.talhouk@ubc.ca",{"name":45,"role":40,"phone":41,"phoneExt":46,"email":13},"Research Assistant","21369",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"VGH Research Pavilion","RECRUITING","Vancouver","British Columbia","V5Z 1M9","Canada","CA",{"type":57,"coordinates":58},"Point",[59,60],-123.11934,49.24966,{"lat":60,"lon":59},[63,64],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},{"name":39,"role":65,"phone":13,"phoneExt":13,"email":13},"PRINCIPAL_INVESTIGATOR",{"type":65,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"Aline Talhouk","Principal Investigator",[70],{"name":71,"class":6},"Vancouver Coastal Health Research Institute","100607899","assessing-uterine-cancer-risk-in-lynch-syndrome-carriers-using-vaginal-self-sampling-and-a-health-questionnaire-100607899",false,"NCT07194551","Assessing Uterine Cancer Risk in Lynch Syndrome Carriers Using Vaginal Self-sampling and a Health Questionnaire","Lynch Syndrome Carriers' Uterine Cancer Health Assessment: Sampling and DNA-based Detection","Lynch-SCAN","Inclusion Criteria:\n\n* Diagnosed with Lynch syndrome (confirmed by genetic testing).\n* Have an intact uterus.\n* Age 30 years or older.\n\nExclusion Criteria:\n\n* History of endometrial cancer or endometrial hyperplasia.\n* History of pelvic radiation or endometrial ablation.\n* Pregnant at the time of study enrolment or during the study.","FEMALE","30 Years",{"count":83,"type":84},30,"ESTIMATED","INTERVENTIONAL",[15],"The goal of this study is to find out if self-collected vaginal swabs can be used to detect early signs of uterine cancer or related conditions in people with Lynch syndrome (LS) who still have their uterus. The study also tests if people with LS are willing and able to collect these samples themselves and whether they find the process acceptable.\n\nThe main questions this study asks are:\n\n* Will people with LS take part in self-collection of vaginal samples, and do they find it acceptable?\n* Can vaginal DNA mutations predict cancer risk or match results from other genetic or biopsy testing?\n* Can a cancer risk model used in the general population also help identify risk in people with LS?\n\nParticipants will:\n\n* Answer a health questionnaire about lifestyle and symptoms\n* Collect their own vaginal swabs and measure their vaginal pH at home using a self-collection kit\n* Complete short surveys around the time of self-collection and at the end of the study",[89,90],"Endometrial Cancer","Lynch Syndrome",[92,90],"Reproductive Health","2026-09-02",{"date":95,"type":96},"2026-09-03","ACTUAL",{"date":98,"type":96},"2025-08-29",{"date":100,"type":84},"2027-04",{"name":5,"class":6},1]